DE68920394D1 - Heterozyklische Verbindungen und Arzneimittel, die die Wirkung von Antikrebsmitteln verstärken, welche diese als wirksame Bestandteile enthalten. - Google Patents

Heterozyklische Verbindungen und Arzneimittel, die die Wirkung von Antikrebsmitteln verstärken, welche diese als wirksame Bestandteile enthalten.

Info

Publication number
DE68920394D1
DE68920394D1 DE68920394T DE68920394T DE68920394D1 DE 68920394 D1 DE68920394 D1 DE 68920394D1 DE 68920394 T DE68920394 T DE 68920394T DE 68920394 T DE68920394 T DE 68920394T DE 68920394 D1 DE68920394 D1 DE 68920394D1
Authority
DE
Germany
Prior art keywords
drugs
potentiate
contain
action
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68920394T
Other languages
English (en)
Other versions
DE68920394T2 (de
Inventor
Nobuyuki Fukazawa
Makoto Odate
Tsuneji Suzuki
Kengo Otsuka
Takashi Tsuruo
Wakao Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc
Publication of DE68920394D1 publication Critical patent/DE68920394D1/de
Application granted granted Critical
Publication of DE68920394T2 publication Critical patent/DE68920394T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE68920394T 1988-10-06 1989-10-06 Heterozyklische Verbindungen und Arzneimittel, die die Wirkung von Antikrebsmitteln verstärken, welche diese als wirksame Bestandteile enthalten. Expired - Lifetime DE68920394T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25089788 1988-10-06
JP15831589 1989-06-22

Publications (2)

Publication Number Publication Date
DE68920394D1 true DE68920394D1 (de) 1995-02-16
DE68920394T2 DE68920394T2 (de) 1995-05-11

Family

ID=26485472

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68920394T Expired - Lifetime DE68920394T2 (de) 1988-10-06 1989-10-06 Heterozyklische Verbindungen und Arzneimittel, die die Wirkung von Antikrebsmitteln verstärken, welche diese als wirksame Bestandteile enthalten.

Country Status (5)

Country Link
US (2) US5112817A (de)
EP (1) EP0363212B1 (de)
KR (1) KR910009199B1 (de)
CA (1) CA1340821C (de)
DE (1) DE68920394T2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
EP0494623A1 (de) * 1991-01-11 1992-07-15 Laboratoires Glaxo Sa Acridinderivate
JP3076672B2 (ja) * 1992-06-18 2000-08-14 三井化学株式会社 キノリン誘導体のフマル酸塩
EP0691962B1 (de) 1993-03-29 2000-09-13 Basf Aktiengesellschaft 1-amino-3-phenoxy-propan-derivate als modulatoren bei multi-drug resistenz
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
JP2000512997A (ja) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー 薬物耐性および多薬物耐性調節物質
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US5776939A (en) * 1997-06-12 1998-07-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
WO2001022968A1 (fr) * 1999-09-30 2001-04-05 Noboru Kaneko Agents anticancereux
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US20020119979A1 (en) * 2000-10-17 2002-08-29 Degenhardt Charles Raymond Acyclic compounds and methods for treating multidrug resistance
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6809093B2 (en) * 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
WO2002042284A1 (fr) * 2000-11-22 2002-05-30 Pola Chemical Industries, Inc. Derives de piperazine dibenzosuberanyle et agents surmontant la resistance aux medicaments contenant ces derives
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CN100343238C (zh) * 2001-11-03 2007-10-17 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR20050092424A (ko) * 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US7462718B2 (en) 2003-05-06 2008-12-09 Schering Ag Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate
DE10321255B4 (de) * 2003-05-06 2006-09-28 Schering Ag Verfahren zur Herstellung von reinstem rac-1{4-[2- Hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarat und reinstes rac-1{4-[2-Hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2
ES2399427T3 (es) * 2003-08-14 2013-04-01 Array Biopharma, Inc. Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
MXPA06002963A (es) * 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
JP2007505878A (ja) * 2003-09-19 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
RU2370494C2 (ru) * 2003-09-19 2009-10-20 Астразенека Аб Производные хиназолина
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MXPA06005462A (es) * 2003-11-14 2006-12-15 Johnson & Johnson Liberacion controlada de topiramato en formas de dosificacion liquida.
CA2555867A1 (en) * 2004-03-04 2005-09-22 Neurogen Corporation Arylalkylamino-substituted quinazoline analogues
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
WO2006023286A2 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
WO2006088541A2 (en) 2005-02-17 2006-08-24 State Of Oregon Acting By & Through The State Board Of Higher Edu. On Behalf Of Portland State Unv. Quinoline derivatives and uses thereof
EP1856095B1 (de) * 2005-02-26 2011-08-24 AstraZeneca AB Chinazolinderivate als tyrosinkinaseinhibitoren
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
WO2007034144A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
EP1940825A1 (de) * 2005-09-20 2008-07-09 Astra Zeneca AB Chinazolinderivat als antikrebsmittel
EP1933811A2 (de) * 2005-09-30 2008-06-25 Alza Corporation Gebundene nanoteilchenförmige dosierformen einer wirkstoffformulierung mit kontrollierter freisetzung und verfahren
KR20080064953A (ko) * 2005-10-13 2008-07-10 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 항균 활성을 갖는 5-퀴놀린 유도체
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CN102887891B (zh) 2005-11-15 2016-03-09 阿雷生物药品公司 N4-苯基-喹唑啉-4-胺衍生物和相关化合物
EP1960371B1 (de) * 2005-12-02 2009-09-16 AstraZeneca AB Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate
EP1957499A1 (de) * 2005-12-02 2008-08-20 AstraZeneca AB 4-anilinosubstituierte chinazolinderivate als tyrosinkinaseinhibitoren
WO2008132738A2 (en) 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
US9321730B2 (en) * 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
WO2009138781A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
CN102603628B (zh) 2010-12-22 2016-08-17 香港理工大学 作为抗癌试剂的喹啉衍生物
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
CN105037265A (zh) * 2015-05-20 2015-11-11 南京大学 一类含查尔酮骨架的喹啉酮衍生物的制备方法及在抗癌药物中的应用
US20180305334A1 (en) * 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
MX2018014032A (es) 2017-03-20 2019-08-21 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr).
CA3082184A1 (en) 2017-12-01 2019-06-06 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP3853206B1 (de) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Behandlung von sichelzellanämie mit einer pyruvatkinase-r-aktivierenden verbindung
CN110963965B (zh) * 2018-09-30 2022-10-18 中国石油化工股份有限公司 防老剂aw生产废渣的回收利用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA645414A (en) * 1962-07-24 P. Walls Leslie Manufacture of quinoline derivatives
US3133925A (en) * 1960-12-22 1964-05-19 Searle & Co Ether derivatives of n-benzhydryl-n'-dihydroxypropylpiperazines and homopiperazines
US4073909A (en) * 1973-10-08 1978-02-14 Sandoz Ltd. Isoquinoline compounds
US4145542A (en) * 1974-06-13 1979-03-20 Otsuka Pharmaceutical Co., Ltd. 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US3983121A (en) * 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
GB2163150B (en) * 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
JPS6147466A (ja) * 1984-08-10 1986-03-07 Dainippon Pharmaceut Co Ltd アミン誘導体
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
DE3600390A1 (de) * 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
US4980351A (en) * 1987-11-04 1990-12-25 Warner-Lambert Company 3-aminopropoxyaryl derivatives having cardiotonic and antihypertensive use and compositions thereof

Also Published As

Publication number Publication date
EP0363212B1 (de) 1995-01-04
EP0363212A2 (de) 1990-04-11
KR900006321A (ko) 1990-05-07
KR910009199B1 (ko) 1991-11-04
US5405843A (en) 1995-04-11
US5112817A (en) 1992-05-12
DE68920394T2 (de) 1995-05-11
CA1340821C (en) 1999-11-16
EP0363212A3 (de) 1991-11-06

Similar Documents

Publication Publication Date Title
DE68920394D1 (de) Heterozyklische Verbindungen und Arzneimittel, die die Wirkung von Antikrebsmitteln verstärken, welche diese als wirksame Bestandteile enthalten.
DE3784905D1 (de) Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten.
DE69824632D1 (de) Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
DE3782182T2 (de) Azacycloalkanderivate, absorptionspromotoren, die die derivate als effektiven inhaltsstoff enthalten und aeusserlich anzuwendende praeparate, die absorptionspromotoren enthalten.
DE69014351T2 (de) Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE3778051D1 (de) Zusammensetzungen, die eine mischung von fluoraufweisenden verbindungen enthalten und die damit behandelten textilien.
NL192721B (nl) Benzonorborneenderivaten, werkwijzen voor het bereiden ervan alsmede geneeskundige en cosmetische preparaten, die dergelijke derivaten bevatten.
DE69600601D1 (de) Heterocyclische, aromatische Verbindungen, pharmazeutische und kosmetische Zusammensetzungen,die sie enthalten, und Verwendungen.
FR2681067B1 (fr) Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
DE3685604T2 (de) 1,7-naphthyridinderivate und diese enthaltende arzneimittel.
DE3779836T2 (de) Iodopropargylcarbamat-derivate, herstellungsverfahren und fungizide mittel, die diese verbindungen enthalten.
DE3788195T2 (de) DIBENZ[b,e]OXEPINDERIVATE, SOWIE ARZNEIMITTEL, DIE DIESE ALS AKTIVE MITTEL ENTHALTEN.
DE69126469T2 (de) Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
FR2703995B1 (fr) 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
DE69002533T2 (de) Indan-1,3-dionderivate und herbizide Zusammensetzungen, die diese als aktiven Bestandteil enthalten.
DE3874390D1 (de) Carboxystyrol-derivate und arzneimittel, die sie als wirkstoff enthalten.
DE68905171D1 (de) Benzol-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die diese enthalten.
DE68900926D1 (de) Pharmazeutische zubereitung, die zidovudin und inosiplex oder bestandteile davon enthaelt, fuer die behandlung von aids-verwandten syndromen.
DE69301261T2 (de) Indan-1,3-Dionderivate und Herbizide, die diese als aktiven Bestandteil enthalten
DE69401151D1 (de) Indenderivate und antimikrobe Mittel, die diese Indenderivate als Aktivkomponente enthalten
DE69012742T2 (de) Azolderivate und fungizide Medikamente, diese als wirkende Komponente enthaltend.
DE69114922D1 (de) Polysulfidverbindungen und Lipidperoxidierungsinhibitore, die diese Polysulfidverbindungen als aktive Zutaten enthalten.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
FR2651129B1 (fr) Nouveaux derives de cysteine; compositions pharmaceutiques ou cosmetiques en contenant.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MITSUI CHEMICALS, INC., TOKIO/TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: SCHERING AG, 13353 BERLIN, DE

8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE